---
title: "Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292772814.md"
description: "Genscript Biotech reported that associate Legend Biotech achieved preliminary net trade sales of approximately US$657 million for CARVYKTI in Q2 2026. While highlighting strong commercial momentum, Genscript cautioned investors that the data is unverified and urged caution regarding regulatory and development risks. Despite these warnings, analyst ratings remain a 'Buy' with a HK$15.50 price target."
datetime: "2026-07-15T12:38:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292772814.md)
  - [en](https://longbridge.com/en/news/292772814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292772814.md)
generator: "portal-rs"
---

# Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution

The latest update is out from Genscript Biotech ( (HK:1548) ).

Genscript Biotech announced that its associate Legend Biotech reported preliminary net trade sales of approximately US$657 million for CARVYKTI for the quarter ended 30 June 2026, under a collaboration and license agreement with Janssen Biotech, Inc. The company cautioned that the sales data, supplied by Janssen, have not been independently verified and emphasized that investors should be aware of the risks and uncertainties affecting Legend’s product development, regulatory outlook and overall performance.

The strong quarterly sales of CARVYKTI highlight the commercial momentum of Legend’s flagship therapy, reinforcing Genscript’s indirect exposure to the fast-growing cell therapy market. However, the detailed risk warnings and forward-looking caveats underline that future results could diverge materially from current trends, urging shareholders and potential investors to exercise caution when dealing in Genscript’s securities.

The most recent analyst rating on (HK:1548) stock is a Buy  
 with a HK$15.50 price target.  
 To see the full list of analyst forecasts on Genscript Biotech stock,  
 see the HK:1548 Stock Forecast page. 

**More about Genscript Biotech**

Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong that focuses on innovative biopharmaceutical products and services. Through its associate Legend Biotech, which is listed on the Nasdaq Global Select Market in the U.S., the group participates in the commercialization of advanced cell therapies targeting oncology indications.

**Average Trading Volume:** 18,585,960

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$31.18B

### Related Stocks

- [01548.HK](https://longbridge.com/en/quote/01548.HK.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

- [Genscript Biotech Clarifies Board Structure and Committee Roles](https://longbridge.com/en/news/296022403.md)
- [GenScript Biotech files HKEX next-day disclosure return, issues 9,272,512 new shares](https://longbridge.com/en/news/296484296.md)
- [GenScript Biotech announces Legend Biotech Form 6-K for Q2 ended June 30, 2026](https://longbridge.com/en/news/295534476.md)
- [HJ Science proposes rebrand to HJ Science Biotech](https://longbridge.com/en/news/296096176.md)
- [Guotai Haitong Keeps Their Buy Rating on Genscript Biotech (GNNSF)](https://longbridge.com/en/news/296605188.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**